CNBC August 21, 2024
Key Points
– Health-care marketplace Sesame announced a new clinical weight loss program that will help eligible consumers access compounded versions of Novo Nordisk’s blockbuster obesity drug Wegovy for $249 per month.
– The company said it is adding compounded semaglutide — the active ingredient in Wegovy and the diabetes injection Ozempic — to its platform to help users safely access obesity and diabetes treatments at a time when many of them are in short supply.
– The program could serve as a more affordable alternative for pursuing weight loss, as compounded medications are typically cheaper than their branded counterparts.
Health-care marketplace Sesame on Wednesday announced a new clinical weight loss program that will help eligible consumers access compounded versions...
Today's Sponsors
Today's Sponsor